Biora Therapeutics, Inc. (NASDAQ:BIOR – Get Free Report) was the recipient of a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 140,800 shares, a drop of 93.4% from the September 30th total of 2,130,000 shares. Based on an average daily volume of 30,500 shares, the days-to-cover ratio is presently 4.6 days. Approximately 4.1% of the shares of the company are short sold.
Biora Therapeutics Price Performance
BIOR stock traded up $0.55 during mid-day trading on Friday, reaching $4.05. 125,692 shares of the company’s stock were exchanged, compared to its average volume of 34,589. The stock’s 50 day moving average is $5.94 and its 200 day moving average is $6.42. Biora Therapeutics has a 12-month low of $3.38 and a 12-month high of $21.10. The company has a market cap of $14.90 million, a price-to-earnings ratio of -0.07 and a beta of 1.22.
Biora Therapeutics (NASDAQ:BIOR – Get Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported ($3.50) earnings per share for the quarter, topping the consensus estimate of ($4.50) by $1.00. The company had revenue of $0.32 million for the quarter. On average, research analysts forecast that Biora Therapeutics will post -12.45 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on Biora Therapeutics
Biora Therapeutics Company Profile
Biora Therapeutics, Inc, a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases.
Featured Articles
- Five stocks we like better than Biora Therapeutics
- 3 Best Fintech Stocks for a Portfolio Boost
- Texas Roadhouse Stock Steering for New Highs This Year
- What is a SEC Filing?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Following Congress Stock Trades
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Biora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.